Quarterly ResultAug 6, 2026, 08:33 AM
Ocugen Q2 Net Loss $24.9M; OCU410 FDA Phase 3 Clearance & RMAT
AI Summary
Ocugen, Inc. reported its second quarter 2026 financial results, including a net loss of $24.9 million. The company announced significant clinical advancements, including FDA clearance to initiate the OCU410 Phase 3 trial for geographic atrophy and the granting of Regenerative Medicine Advanced Therapy (RMAT) designation for OCU410. Financially, Ocugen closed a $130.0 million convertible senior notes financing, extending its cash runway into 2028, and signed a binding term sheet for an exclusive OCU400 license in the MENA region with potential milestones up to $255 million.
Key Highlights
- Received FDA clearance for OCU410 Phase 3 trial for geographic atrophy.
- OCU410 granted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA.
- Closed $130.0 million convertible senior notes financing, extending cash runway into 2028.
- Signed binding term sheet for OCU400 license in MENA region, up to $255M milestones.
- Reported Q2 2026 net loss of $24.9 million, compared to $14.7 million in Q2 2025.
- Cash, cash equivalents, and restricted cash totaled $100.4 million as of June 30, 2026.
- Research and development expenses increased to $10.7 million from $8.4 million year-over-year.
- Anticipates OCU400 (RP) topline results in Q1 2027 and OCU410ST (Stargardt) in Q2 2027.
Price Impact
More from OCGN